TOP PHARMACEUTICAL COMPANIES BY REVENUES IN 2024
Sl No | Company | Q1 | Q2 | Q3 | Total | Best selling products |
1 | JOHNSON AND JOHNSON | $21.8 | $43.8 | $66.1 | Stelara, Darzalex, Imbruvica | |
2 | ROCHE | $15.8 | $34.8 | $51.9 | Ocrevus, Perjeta, Tecentriq, Hemlibra, Kadcyla, Alecensa, Mabthera/Rituxan | |
3 | PFIZER | $14.9 | $28.2 | $45.9 | Comirnaty, Paxlovid, Prevenar 13, Ibrance, Eliquis | |
4 | MERCK | $14.0 | $28.4 | $43.4 | Keytruda, Lagevrio, Januvia, Gardasil/Gardasil9 | |
5 | ABBVIE | $12.3 | $26.8 | $41.2 | Skyrizi, Rinvoq, Humira, Imbruvica, Venclexta | |
6 | ASTRAZENECA | $12.2 | $24.6 | $39.2 | Tagrisso, Farxiga, Imfinzi | |
7 | SANOFI | $12.4 | $23.2 | $37.4 | Dupixent | |
8 | NOVARTIS | $11.8 | $24.3 | $37.2 | Entresto, Cosentyx | |
9 | BMS | $11.9 | $23.5 | $35.9 | Opdivo, Eliquis, Orencia | |
10 | ABBOTT | $10.0 | $20.4 | $31.0 | ||
11 | NOVO NORDISK | $9.4 | $28.9 | Ozempic, Victoza, Tresiba, NovoMix, NovoRapid, NovoSeven | ||
12 | GSK | $9.3 | Dolutegravir products, Nucala, Xevudy | |||
13 | TAKEDA | |||||
14 | ELI LILLY | $8.8 | Trulicity, Humalog, Alimta, Taltz | |||
15 | AMGEN | Prolia, Otezla, Enbrel, Blincyto |
1. JOHNSON AND JOHNSON
Q1 REVENUES:
In the first quarter of 2024, Johnson & Johnson reported sales growth of 2.3%, reaching $21.4 billion. The operational growth was 3.9%, and the adjusted operational growth (excluding COVID-19 Vaccine impact) stood at 4.0%. Notably, adjusted operational growth, excluding the vaccine, was an impressive 7.7%.
Best selling drugs
Q2 REVENUES
In the second quarter of 2024, reported sales increased by 4.3%, reaching $22.4 billion. The company saw an operational growth of 6.6% and an adjusted operational growth of 6.5%.
Excluding the COVID-19 vaccine, global operational sales for Innovative Medicine rose by 8.8%. This growth was primarily driven by products such as Darzalex (daratumumab), Erleada (apalutamide), and other oncology treatments, as well as Tremfya (guselkumab) and Stelara (ustekinumab) in the immunology sector, and Spravato (esketamine) in neuroscience. However, this growth was somewhat offset by declines in other neuroscience products.
Q3 REVENUES
In the third quarter of 2024, Johnson and Johnson reported sales saw an increase of 5.2%, reaching $22.5 billion. Operational growth stood at 6.3%, with adjusted operational growth at 5.4%.
Revenues from innovative medicines amounted to $14.6 billion. Stelara's revenues experienced a decline of 6.6%, totaling $2.68 billion. On the other hand, Tremfya generated $1.0 billion in revenue, reflecting a 13% growth. Darzalex brought in $3.0 billion, marking a significant 21% rise in revenue.
2. ROCHE
Q1 RESULTS:
Sales Decline: In the first quarter of 2024, Roche reported a 6% decline in sales, amounting to 14.4 billion Swiss francs (approximately $15.80 billion). This decrease was attributed to the impact of foreign exchange rates and the loss of revenue from COVID-related products.
Pharmaceutical Division: The pharmaceutical division’s performance also slowed, with sales dropping to $11.96 billion from $12.71 billion in the same period last year.
Q3 RESULTS:
Group sales rose by 6% at constant exchange rates (CER) (2% in CHF) in the first nine months, mainly due to strong demand for medicines and diagnostics. Excluding COVID-19-related products, the sales growth reached 8%.
In the third quarter, Group sales showed a 9% increase (6% in CHF), consistent with the growth seen in the second quarter.
The Pharmaceuticals Division saw a 7% rise in sales over the first nine months, with a 9% increase in the base business. This growth was driven by high demand for newer treatments for severe illnesses, with major contributors including Vabysmo (for serious eye conditions), Phesgo (for breast cancer), and Ocrevus (for multiple sclerosis).
Best-selling drugs of 2024
Sl No | Brand | Revenues |
1 | Ocrevus | $5.8 billion |
2 | Hemlibra | $ 3.8 billion |
3 | Vabysmo | $3.2 billion |
3. PFIZER
Pfizer reported total revenues of $14.9 billion for Q1 2024.
Eliquis | $2.0 billion |
Paxlovid | $2.0 billion |
Ibrance | $1.0 billion |
4. ABBVIE
AbbVie delivered first-quarter net revenues of $12.310 billion, showing a modest increase of 0.7% on a reported basis and 1.6% on an operational basis.
Humira | $2.3 billion |
Skyrizi | $2.0 billion |
Rinvoq | $1.0 billion |
5. MERCK
Q1 RESULTS:
Merck reported continued strong growth in oncology and vaccines. Total worldwide sales for Q1 2024 were $14.0 billion.
Keytruda revenues were $6.9 billion, an increase of 20% revenues compared to previous year.
Keytruda | $6.9 billion |
Gardasil/Gardasil 9 | $2.2 billion |
6. SANOFI
Q1 REVENUES
Sanofi achieved a 6.7% sales growth at constant exchange rates (CER), with net sales totaling $12.4 billion. Dupixent revenues were $3.4 billion, and expected revenues were $14.0 billion.
7. NOVARTIS
Q1 REVENUES
Sales Growth: The company reported a 25% increase in net income from continuing operations, reaching $2.68 billion compared to $2.15 billion in Q1 2023.
Q3 REVENUES
Novartis generated USD 37.1 billion in revenue in the first nine months. The main drivers of this growth were strong sales from Entresto, which reached USD 5.6 billion with a 28% increase overall; Cosentyx, at USD 4.5 billion with a 24% increase; Kesimpta, which achieved USD 2.3 billion, growing by 49%; Kisqali, at USD 2.1 billion with a 45% overall growth.
Sl No | Brand | Revenues |
1 | Entresto | $5.6 billion |
2 | Cosentyx | $4.5 billion |
3 | Kesimpta | $2.2 billion |
8. ASTRAZENECA
9. BMS
In the first quarter, Bristol Myers Squibb reported revenues of $11.9 billion, marking a 5% increase, or 6% when accounting for foreign exchange effects. This growth was primarily fueled by strong performances from Eliquis, Reblozyl, and Opdualag, although somewhat tempered by declines in Opdivo and Revlimid sales.
In the U.S., revenues rose by 7% to $8.5 billion, driven by the success of Eliquis, Reblozyl, and Opdualag, offsetting declines in Revlimid. Opdivo revenues saw a decrease from $1.3 billion to $1.2 billion, down by 10%, mainly due to inventory adjustments and timing of orders, despite underlying demand growth.
Meanwhile, international revenues remained relatively steady at $3.4 billion, as increased demand for Opdivo, Yervoy, and Reblozyl offset lower selling prices. Foreign exchange fluctuations had a 5% adverse impact on revenues.
10. ABBOTT
Comentários